Interplay between miRNAs and Mycobacterium tuberculosis: diagnostic and therapeutic implications

•Current intervention measures for tuberculosis (TB) treatment are far from satisfactory.•Mycobacteria alter the host microRNA (miRNA) expression profile to their benefit.•miRNAs based biomarkers have the potential for early diagnosis of TB.•miRNA offer enormous potential as future therapeutics for...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2021-05, Vol.26 (5), p.1245-1255
Main Authors: Singh, Amit Kumar, Ghosh, Mrinmoy, Kumar, Vimal, Aggarwal, Sumit, Patil, Shripad A.
Format: Article
Language:English
Subjects:
Animals
Antitubercular Agents - administration & dosage
Biomarkers - metabolism
Humans
MicroRNAs - genetics
Mycobacterium tuberculosis - genetics
Oligonucleotides - administration & dosage
Tuberculosis - genetics
Tuberculosis - microbiology
Tuberculosis - therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Current intervention measures for tuberculosis (TB) treatment are far from satisfactory.•Mycobacteria alter the host microRNA (miRNA) expression profile to their benefit.•miRNAs based biomarkers have the potential for early diagnosis of TB.•miRNA offer enormous potential as future therapeutics for TB treatment.•miRNA therapeutics success will depend on development of efficient delivery system. Increasing evidence suggests that mycobacteria change the host miRNA profile to their advantage. The active participation of miRNAs in controlling immune responses in TB has raised the possibility of utilizing miRNA-based therapy itself or canonically with a standard drug regimen for shortening the duration of treatment. The development of delivery systems for optimal delivery of oligonucleotides, including small interfering (si)RNA/miRNAs-based therapeutics has shown potential as a new therapeutic intervention. However, studies related to the exploitation of miRNAs as both biomarkers and as therapeutics in TB are scarce; thus, more in vitro and in vivo studies are required to fully determine the role of miRNAs as potential diagnostic biomarkers and to improve the pharmacological profile of this class of therapeutics.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2021.01.021